Related Experiment Video
Updated: Jul 11, 2026

Potentiation of Anticancer Antibody Efficacy by Antineoplastic Drugs: Detection of Antibody-drug Synergism Using the Combination Index Equation
Published on: January 19, 2019
A Phase I trial of weekly docetaxel and topotecan for solid tumors
Wan Teck Lim1, Maria Q Baggstrom, William Read
1Alvin J Siteman Cancer Center, Washington University School of Medicine, 660 South Euclid Avenue, St Louis, MO 63110, USA.
Background/Aims:
Topotecan and docetaxel are active agents in the treatment of various malignant diseases. Both drugs cause dose-limiting hematologic toxicity. This study defines the maximum tolerated dose (MTD) and dose-limiting toxicity of weekly topotecan when administered in combination with docetaxel 25 mg/m(2) given day 1, 8,15 every 28 days.
Methods:
Thirteen patients were enrolled. Median age was 62 years. Majority of the patients had lung cancer.
Results:
The maximum tolerated dose was docetaxel 25 mg/m(2) and topotecan 3 mg/m(2) administered weekly. Dose-limiting toxicity was febrile neutropenia. Eight patients developed at least grade 3 neutropenia in all cycles. Non-hematologic toxicities were mild. No objective responses were noted. Two patients with non-small cell lung cancer had stable disease as a best response.
Conclusion:
Combination docetaxel and topotecan given weekly is tolerable. The recommended phase II dose is docetaxel 25 mg/m(2) and topotecan 3 mg/m(2) day 1, 8, 15 every 28 days.
Related Concept Videos
Clinical Trials: Overview
Treatment Resistent Cancers
Treatment Resistant Cancers
Clinical Trials
There are four phases in a clinical trial. A phase one...
Targeted Cancer Therapies
There are several types of targeted therapies against specific...
Targeted Cancer Therapies
There are several types of targeted therapies against specific...

